Transneuronix, Inc. was founded in 1995 and was based in Mount Arlington, New Jersey. It was acquired by Medtronic in 2005.
Before its acqusition by Medtronic, Transneuronix developed the Transcend, an implantable gastric stimulator device for the treatment of obesity by electrical stimulation of the stomach. Later, Medtronic developed the Transcend II IPG.
In December 2005, Medtronic announced that the preliminary results of the Screened Health Assessment and Pacer Evaluation, or SHAPE trial using the Transcend device, did not meet the efficacy endpoint of a difference in mean excess weight loss at one year.
Click here for Transneuronix’s patents.